This will take effect March 28, 2013
Overview and Clinical Utility:
Effective March 28, 2013, PathGroup will implement in-house testing for 1,5 Anhydroglucitol (GlycoMark®). GlycoMark® is a newly FDA approved blood test which measures 1,5 anhydroglucitol (1,5-AG), a glucose analogue in serum or EDTA plasma, for the intermediate-term monitoring of glycemic control in individuals with diabetes.
Click Here to read more.